Beta Bionics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean T. Saint
- Full Time Employees
- 352
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Address
- 11 Hughes Irvine CA United States of America 92618
- IPO Date
- Jan 30, 2025
- CIK
- 0001674632
- Website
- betabionics.com
- Similar Companies
- Business
- Beta Bionics, Inc. (NASDAQ:BBNX) develops and commercializes automated insulin delivery systems for people with insulin-dependent diabetes. The company offers the iLet Bionic Pancreas, an FDA-cleared autonomous insulin delivery device for adults and children aged six years and older that integrates with Dexcom or FreeStyle Libre 3 Plus continuous glucose monitors to automatically compute and deliver insulin doses without requiring carb counting, correction factors, or preset basal rates; a Color iLet variant featuring a color screen and enhanced alerts; and related monthly supplies. Beta Bionics develops additional pipeline products including a tubeless Patch Pump that adheres directly to the skin, a Bihormonal iLet combining automated insulin and glucagon delivery, and an iLet configuration for insulin-dependent type 2 diabetes. Founded in 2015 and headquartered in Irvine, California, with operations in Massachusetts, the company targets people with diabetes globally, emphasizing simplified management through adaptive algorithms. Beta Bionics maintains strategic partnerships, including a collaboration and license agreement with Xeris Pharmaceuticals, Inc. for a pump-compatible glucagon formulation and a development agreement with Abbott Diabetes Care Inc. for automated insulin delivery systems. In November 2024, Beta Bionics closed a $60 million Series E funding round led by Wellington Management with participation from existing investors including Eventide Asset Management and RTW Investments to support iLet commercialization, pipeline advancement, and manufacturing expansion. The company completed its initial public offering on NASDAQ in January 2025 and reported full-year 2024 revenue of $65.1 million, reflecting 443% year-over-year growth and an install base exceeding 15,000 users. Beta Bionics continues to pursue pharmacy reimbursement for the iLet system while advancing bihormonal and patch pump initiatives.
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fid
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders
Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review
Beta Bionics to Present at the Bank of America Securities Health Care Conference
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026